iobitridol

a nonionic monomeric low-osmolality contrast medium; structure given in second source

Also Known As:

5-(3-hydroxy-2-hydroxymethylpropionamido)-N,N'-dimethyl-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide; Xenetix

Networked: 26 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzoates: 426
        Iodobenzoates
        Triiodobenzoic Acids: 2
        Iohexol: 681
        iobitridol: 26
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Benzoates: 426
      - Iodobenzoates
        Triiodobenzoic Acids: 2
        Iohexol: 681
        iobitridol: 26

Experts

1.	Assier, H: 1 article (04/2020)
2.	Chosidow, O: 1 article (04/2020)
3.	Deschamps, O: 1 article (04/2020)
4.	Duong, T A: 1 article (04/2020)
5.	Gaudin, O: 1 article (04/2020)
6.	Gener, G: 1 article (04/2020)
7.	Ingen-Housz-Oro, S: 1 article (04/2020)
8.	Luciani, A: 1 article (04/2020)
9.	Paul, M: 1 article (04/2020)
10.	Wolkenstein, P: 1 article (04/2020)

Related Diseases

1.	Neoplasms (Cancer) 10/19/2017 - "(ii) high drug loading (177% by weight), (iii) controlled drug release triggered by NIR light and moderate acidic pH, (iv) high tumor accumulation via heat-enhanced tumor vascular permeability, (v) complete tumor ablation and negligible side effects, and (vi) comparable CT imaging contrast efficiency to the widely clinically used agent iobitridol. " 06/01/2019 - "Iopamidol, iohexol, and iobitridol showed higher efficacy in MDR cancer cells than for the corresponding sensitive cancer cells by approximately 2 fold. " 06/01/2019 - "However, there were notable changes detected for iobitridol and iodixanol at 50 mgI/mL. Similarly, the results showed significant differences in P-glycoprotein function of K562/Dox cancer cells after treatment with IRCM when compared to the non-treated K562/Dox cancer cells, with iohexol and iodixanol being the notable exceptions once again. " 06/01/2019 - "The aim of this present study was to examine five iodinated radiographic contrast media (IRCM) (i.e., iohexol, iopamidol, iobitridol, ioxaglate, and iodixanol) in terms of their cytotoxicity, mitochondria membrane potential (ΔΨm), and P-glycoprotein function in multidrug resistant K562/Dox cancer cells and corresponding sensitive cancer cells. "
2.	Cortical Blindness (Anton Syndrome) 01/01/2007 - "Transient cortical blindness after cardiac catheterization with iobitridol." 01/01/2007 - "In this study, we present a case of abrupt cortical blindness after exposure to contrast media during diagnostic coronary angiography; to our knowledge, this is the 1st report in the medical literature that describes transient cortical blindness after iobitridol use."
3.	Pulmonary Embolism 09/01/2001 - "This study confirmed that P743 remains more intravascular than iobitridol, which may have clinical implications for the diagnosis of pulmonary embolism, for example."
4.	Renal Cell Carcinoma (Grawitz Tumor) 08/01/2010 - "In two phase-III trials involving 51 patients with metastatic renal cell carcinoma (38 men, 13 women; age range, 30-80 years) receiving antiangiogenic drugs (sorafenib [n = 10], sunitinib [n = 22]), a placebo (n = 12), or interferon alfa (n = 7), serial dynamic contrast-enhanced CT was performed, during 90 seconds before and after injection of 80 mL of iobitridol. "
5.	Nausea 07/01/2018 - "Multivariate regression analysis revealed that a history of drug hypersensitivity [odds ratio = 4.33; 95% CI (1.85-17.52); p = 0.039] was independent risk factors for nausea, whereas iobitridol was less nauseous [odds ratio = 0.32; 95% CI (0.11-0.90); p = 0.032]. " 01/01/1996 - "Excluding a heat sensation, 5 of the patients who received iobitridol had minor reactions consisting of nausea with vomiting and pain during the injection. "

Related Drugs and Biologics

1.	Contrast Media
2.	Iohexol (Omnipaque)
3.	Iopamidol (Isovue)
4.	iodixanol (Visipaque)
5.	Ioxaglic Acid (Ioxaglate Meglumine)
6.	Member 1 Subfamily B ATP Binding Cassette Transporter
7.	Interferon-alpha (Interferon Alfa)
8.	Sunitinib (Sutent)
9.	Sorafenib (BAY 43-9006)
10.	P743

Related Therapies and Procedures

1.	Stents
2.	Electric Countershock (Cardioversion)
3.	Aftercare (After-Treatment)